Novo Nordisk signs second licensing deal after investor backlash

Novo Nordisk announced its second licensing agreement since a poorly received capital-markets day, signaling a strategic pivot to bolster its pipeline amid investor concerns. The deal follows a frosty reception to its long-term strategy, suggesting management is responding to market pressure. The financial terms and specific assets are undisclosed, leaving the impact on growth prospects uncertain.